London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as ...
Oxford, UK – 24 September 2026: OXB (LSE: OXB) (the “Company”), a global quality and innovation-led cell and gene therapy CDMO, today announces that Dr. Roch Doliveux, a Non-Executive Director and ...
BARCELONA, Spain, Sept. 23, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that the global contract development and manufacturing organization, Oxford Biomedica (OXB) will drive its ...
OXB (OXB), formerly Oxford BioMedica, enjoyed a steady first half after the contract medicines manufacturer reported a 9 per cent increase in revenues to £79.8mn, as new client wins and stronger ...
First-half performance improved: Revenue rose 10% at constant currency to £80.2 million, led by a 20% increase in manufacturing revenue. Adjusted EBITDA loss narrowed to £2.5 million, although OXB ...
It has thus far refused four £9 offers from Swedish investment firm EQT, which is said to be looking at Oxford BioMedica plc (LON: OXB) again now that shares are below 500p. But now AstraZeneca (LON: ...
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two ...
Oxford BioMedica의 최근 분기 수익은 얼마였나요? Oxford BioMedica의 EPS(TTM)는 -0.27입니다. Oxford BioMedica의 최근 분기 보고된 매출은 95.52, 순이익은 -3.77, EPS는 -0.05입니다. Oxford BioMedica의 최근 분기 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results